Roche boosts can­cer ap­provals in Eu­rope, push­ing for a big­ger slice of the I/O pie

Roche is stack­ing up ap­provals for its flag­ship check­point in­hibitor in the lu­cra­tive field of lung can­cer. On Fri­day, the Swiss drug­mak­er re­vealed that the Eu­ro­pean Com­mis­sion had en­dorsed the use of Tecen­triq in com­bi­na­tion with chemother­a­py as the first line of de­fense in cer­tain pa­tients with ad­vanced non-squa­mous non-small cell lung can­cer (NSCLC).

The ap­proval comes on the ba­sis of the 723-pa­tient IM­pow­er130 study, which test­ed the drug plus chemo against chemo alone, in pa­tients with stage IV metasta­t­ic non-squa­mous NSCLC, who are not car­ry­ing EGFR or ALK mu­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER